Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye provides a research update following the Q1 report published by OncoZenge earlier today.</li><li>The report was largely in line with our expectations, aside from a deviation in the cash flow metrics stemming from a negative change in working capital.</li><li>Importantly, in correlation with the report, the company announced that the CTA for the pivotal Phase III study has now received final approval, enabling study initiation.</li></ul>

Redeye provides a research update following the Q1 report published by OncoZenge earlier today.The report was largely in line with our expectations, aside from a deviation in the cash flow metrics stemming from a negative change in working capital.Importantly, in correlation with the report, the company announced that the CTA for the pivotal Phase III study has now received final approval, enabling study initiation.

OncoZenge (Q1 Review): Final CTA approval received, initiating pivotal study

Oncozenge

OncoZenge (Q1 Review): Final CTA approval received, initiating pivotal study